Journal of Thrombosis and Thrombolysis

, Volume 42, Issue 4, pp 486–493 | Cite as

Patient satisfaction with extended-interval warfarin monitoring

  • Nicholas W. Carris
  • Andrew Y. Hwang
  • Steven M. Smith
  • James R. Taylor
  • Karen Sando
  • Jason Powell
  • Eric I. Rosenberg
  • Marc S. Zumberg
  • John G. Gums
  • Eric A. Dietrich
  • Katherine Vogel Anderson
Article

Abstract

Extended-interval monitoring of warfarin has been proposed to reduce follow-up burden and improve patient satisfaction. We aimed to make an initial assessment of anticoagulation satisfaction before and after an extended-interval warfarin monitoring intervention. We conducted a translational prospective single-arm pilot study of extended-interval warfarin monitoring in five pharmacist-managed anticoagulation clinics. Patients meeting CHEST guideline criteria for extended-interval warfarin monitoring began progressive extended-interval follow-up (6, 8, and 12 weeks thereafter). The Duke Anticoagulation Satisfaction Scale (DASS) was administered at baseline and at end-of-study or study removal (in patients no longer appropriate for extended interval follow-up). Forty-six patients had evaluable pre- and post-intervention DASS survey data. Mean age of patients was 66.5 years, 74 % were non-Hispanic whites, and 48 % were men. Patients completed a mean ± SD of 34 ± 22 weeks of follow-up. Mean ± SD total DASS score at baseline was 45.2 ± 14.2 versus 49.1 ± 14.9 at end-of-study (mean change, +3.9 [95 % CI −0.6–8.4; p = 0.09]), indicating no benefit—and trending toward decrement—to anticoagulation satisfaction. Change in anticoagulation satisfaction varied substantially following extended-interval monitoring, with no evidence of improved satisfaction. Plausible reasons for patients not preferring extended-interval monitoring include increased anxiety and disengagement from self-management activities, both potentially related to less frequent feedback and reassurance during extended interval-monitoring. Additional research is needed to identify who is likely to benefit most from extended-interval monitoring. Anticoagulation satisfaction should be considered with clinical factors and shared-decision making when implementing extended-interval warfarin monitoring.

Keywords

Anticoagulation Warfarin Interval Monitoring Patient satisfaction 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Marc S. Zumberg reports being the medical director for NCF diagnostics and DNA technology.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ (2012) Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):7S–47SCrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e44S–e88SCrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352CrossRefPubMedGoogle Scholar
  4. 4.
    Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184SCrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M (2011) Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 155(10):653–659CrossRefPubMedGoogle Scholar
  6. 6.
    Pengo V, Barbero F, Biasiolo A, Pegoraro C, Cucchini U, Iliceto S (2003) A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. Am J Clin Pathol 120(6):944–947CrossRefPubMedGoogle Scholar
  7. 7.
    Fihn SD, McDonell MB, Vermes D, Henikoff JG, Martin DC, Callahan CM et al (1994) A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics. J Gen Intern Med 9(3):131–139CrossRefPubMedGoogle Scholar
  8. 8.
    Carris NW, Spinelli A, Pierini D, Taylor JR, Anderson KV, Sando K et al (2015) Feasibility of extended-interval follow-up for patients receiving warfarin. Cardiovasc Ther 33(3):98–103CrossRefPubMedGoogle Scholar
  9. 9.
    Samsa G, Matchar DB, Dolor RJ, Wiklund I, Hedner E, Wygant G et al (2004) A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes 2:22CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Harris PA, Taylor R, Thielke R et al (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381CrossRefPubMedGoogle Scholar
  11. 11.
    Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS et al (2010) Effect of home testing of international normalized ratio on clinical events. N Engl J Med 363(17):1608–1620CrossRefPubMedGoogle Scholar
  12. 12.
    Verret L, Couturier J, Rozon A, Saudrais-Janecek S, St-Onge A, Nguyen A et al (2012) Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial. Pharmacotherapy 32(10):871–879CrossRefPubMedGoogle Scholar
  13. 13.
    Meyer S, Frei CR, Daniels KR, Forcade NA, Bussey M, Bussey-Smith KL et al (2013) Impact of a new method of warfarin management on patient satisfaction, time, and cost. Pharmacotherapy 33(11):1147–1155CrossRefPubMedGoogle Scholar
  14. 14.
    McCahon D, Murray ET, Murray K, Holder RL, Fitzmaurice DA (2011) Does self-management of oral anticoagulation therapy improve quality of life and anxiety? Fam Pract 28(2):134–140CrossRefPubMedGoogle Scholar
  15. 15.
    Wigle P, Hein B, Bloomfield HE, Tubb M, Doherty M (2013) Updated guidelines on outpatient anticoagulation. Am Fam Physician 87(8):556–566PubMedGoogle Scholar
  16. 16.
    Hasan SS, Teh KM, Ahmed SI, Chong DW, Ong HC, Naina B (2015) Quality of life (QoL) and International normalized ratio (INR) control of patients attending anticoagulation clinics. Public Health 129(7):954–962CrossRefPubMedGoogle Scholar
  17. 17.
    Almeida Gde Q, Noblat Lde A, Passos LC, do Nascimento HF (2011) Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Qual Life Outcomes 9:91CrossRefPubMedGoogle Scholar
  18. 18.
    Casais P, Meschengieser SS, Sanchez-Luceros A, Lazzari MA (2005) Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin 21(7):1085–1090CrossRefPubMedGoogle Scholar
  19. 19.
    Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J (2013) Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol 168(3):2540–2547CrossRefPubMedGoogle Scholar
  20. 20.
    Alegret JM, Vinolas X, Arias MA, Martinez-Rubio A, Rebollo P, Rafols C et al (2014) New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. Int J Med Sci 11(7):680–684CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, Cano SJ (2013) Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 110(4):732–741CrossRefPubMedGoogle Scholar
  22. 22.
    Shore S, Ho PM, Lambert-Kerzner A, Glorioso TJ, Carey EP, Cunningham F et al (2015) Site-level variation in and practices associated with dabigatran adherence. JAMA 313(14):1443–1450CrossRefPubMedGoogle Scholar
  23. 23.
    Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L et al (2014) Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 167(6):810–817CrossRefPubMedGoogle Scholar
  24. 24.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMedGoogle Scholar
  25. 25.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104CrossRefPubMedGoogle Scholar
  26. 26.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891CrossRefPubMedGoogle Scholar
  27. 27.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRefPubMedGoogle Scholar
  28. 28.
    Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808CrossRefPubMedGoogle Scholar
  29. 29.
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352CrossRefPubMedGoogle Scholar
  30. 30.
    Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510CrossRefPubMedGoogle Scholar
  31. 31.
    Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415CrossRefPubMedGoogle Scholar
  32. 32.
    Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P et al (2008) Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 1(2):84–91CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Nicholas W. Carris
    • 1
    • 2
  • Andrew Y. Hwang
    • 3
    • 4
  • Steven M. Smith
    • 3
    • 4
  • James R. Taylor
    • 3
  • Karen Sando
    • 3
    • 4
  • Jason Powell
    • 3
  • Eric I. Rosenberg
    • 5
  • Marc S. Zumberg
    • 6
  • John G. Gums
    • 3
    • 4
  • Eric A. Dietrich
    • 3
    • 4
  • Katherine Vogel Anderson
    • 3
    • 5
  1. 1.Department of Pharmacotherapeutics and Clinical Research, College of PharmacyUniversity of South FloridaTampaUSA
  2. 2.Department of Family Medicine, Morsani College of MedicineUniversity of South FloridaTampaUSA
  3. 3.Department of Pharmacotherapy and Translational Research, College of PharmacyUniversity of FloridaGainesvilleUSA
  4. 4.Department of Community Health and Family Medicine, College of MedicineUniversity of FloridaGainesvilleUSA
  5. 5.Division of General Internal Medicine, College of MedicineUniversity of FloridaGainesvilleUSA
  6. 6.Division of Hematology/Oncology, College of MedicineUniversity of FloridaGainesvilleUSA

Personalised recommendations